Meda AB
{{short description|Swedish healthcare company}}
{{Infobox company
| name = Meda AB
| foundation = {{Start date and age|1991|06|06}}
| location_city = Solna
| location_country = Sweden
| revenue = SEK 15 billion {{small|(2014)}}
| num_employees = 5,202 {{small|(2014)}}
| divisions = MedPointe
| parent = Viatris
}}
Meda AB is a specialty pharmaceutical company, headquartered in Solna, Sweden. Meda imports and markets pharmaceuticals, nutritional, and health-care products, and offers services including clinical research, registration, and logistics. At the end of 2014, Meda had 5,202 employees. Meda's pharmaceuticals are currently sold in more than 150 countries.{{cite web|title = About Meda|url = http://www.meda.se/about-meda/|accessdate = 15 August 2015|publisher = Meda AB}}{{Self-published inline|date = August 2015|certain = yes}}
Meda was listed on the Stockholm Stock Exchange until it was acquired by Mylan in 2016 through a cash and stock offer valued €7.2 billion.{{Cite web|url=https://www.pharmastar.it/news/business/mylan-compra-meda-affare-da-7-2-miliardi-20600|title=Mylan compra Meda, affare da $7,2 miliardi|website=www.pharmastar.it|access-date=15 July 2021}}
Mergers, acquisitions and divestments
In 2005, Meda bought German pharmaceutical brand Viatris GMBH from
Advent International for €750million ($926 million). https://invivo.citeline.com/deals/200510151
On 20 July 2007, Meda announced an $800 million cash-and-stock deal to buy the New Jersey–based pharmaceutical company MedPointe from a group of U.S. investors. MedPointe bought the diagnostics and drug businesses of Carter-Wallace in 2001, with the consumer product line going to Church & Dwight.{{Cite web|url=https://www.cnbc.com/2007/07/20/meda-to-buy-medpointe-for-800-million-in-cash-stock.html|title = Meda to Buy MedPointe for $800 Million in Cash, Stock|website = CNBC|date = 20 July 2007}} The deal was completed on 22 August with Meda entering the US market. The new shareholders in Meda are The Carlyle Group, The Cypress Group LLC, and other US investors, who had a combined shareholding in Meda of approximately 7%.{{Cite press release|url=https://www.globenewswire.com/news-release/2007/08/22/87789/0/en/Strategic-acquisition-of-MedPointe-Inc-completed.html|title = Strategic acquisition of MedPointe Inc completed|date = 22 August 2007}}
In 2014, Meda acquired the Italian firm Rottapharm Madaus in order to add consumer health products to their portfolio.{{Cite news|url = https://www.bloomberg.com/news/articles/2015-08-27/swedish-drugmaker-meda-said-to-explore-sale-of-u-s-operations|title = Swedish Drugmaker Meda Said to Weigh Sale of U.S. Operations|last1 = Ewing|first1 = Adam|date = 27 August 2015|access-date = 28 August 2015|last2 = Baigorri|first2 = Manuel|agency = Bloomberg Business}} Meda explored in 2015 the possibility of divesting its United States division, Meda Pharmaceuticals, to raise funds for expansion in other areas.